Bio-Rad LaboratoriesFRA:BUWA +1.48%72 PE Ratio without NRI is 34.04 as of Jul. 02, 2026, which is 21% below its 10-year median of 43.17. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €278.74 (Fairly Valued). The stock has 5 warning signs investors should review. Among 446 Medical Devices & Instruments companies, Bio-Rad Laboratories ranks worse than 64.8% on this metric.
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-02), Bio-Rad Laboratories's share price is €260.40.
Bio-Rad Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €7.65. Therefore, Bio-Rad Laboratories's PE Ratio without NRI for today is 34.04.
During the past 13 years, Bio-Rad Laboratories's highest PE Ratio without NRI was 110.75. The lowest was 22.59. And the median was 43.17.
Bio-Rad Laboratories's EPS (Basic) for the
three
months ended in Mar. 2026 was €-16.91.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.18.
Bio-Rad Laboratories (FRA:BUWA) PE Ratio without NRI Explanation
The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.
If a company loses money, the PE Ratio becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.
Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.
Bio-Rad Laboratories PE Ratio without NRI Related Terms
Bio-Rad Laboratories PE Ratio without NRI Historical Data
* Premium members only.
The historical data trend for Bio-Rad Laboratories's PE Ratio without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:BUWA vs GKOS, BRKR, PODD: PE Ratio without NRI Comparison
For the Medical Devices subindustry, Bio-Rad Laboratories's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Rad Laboratories PE Ratio without NRI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's PE Ratio without NRI falls into.
Bio-Rad Laboratories PE Ratio without NRI Calculation
The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.
Bio-Rad Laboratories's Share Price of today is €260.40.
Bio-Rad Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.65.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.
For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
Bio-Rad Laboratories (FRA:BUWA) has a PE Ratio without NRI of 34.04 as of Jul. 02, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Bio-Rad Laboratories and its competitors. This is 21% below median its historical median of 43.17. Over the past decade, Bio-Rad Laboratories' PE Ratio without NRI has ranged from 22.59 to 110.75. According to the industry distribution chart, Bio-Rad Laboratories ranks #289 out of 446 companies in the Medical Devices & Instruments industry, placing it in the top 64.8%.
Is Bio-Rad Laboratories' PE Ratio without NRI too high?
Bio-Rad Laboratories' current PE Ratio without NRI of 34.04 is 21% below median its 10-year median of 43.17. Over the past 10 years, this metric has ranged from a low of 22.59 to a high of 110.75. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.62. Bio-Rad Laboratories' value of 34.04 is 44.1% above this industry median. Based on the distribution chart, Bio-Rad Laboratories ranks #289 out of 446 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' PE Ratio without NRI compare to GKOS and BRKR?
According to the Medical Devices & Instruments industry distribution chart, Bio-Rad Laboratories ranks #289 out of 446 companies for PE Ratio without NRI. This places Bio-Rad Laboratories in the lower half of its industry. The industry median PE Ratio without NRI is 23.62. Bio-Rad Laboratories' value of 34.04 is 44.1% above this benchmark. Historically, Bio-Rad Laboratories' own PE Ratio without NRI has ranged from 22.59 to 110.75 over the past decade. While the company's 10-year median is 43.17 vs. the industry median of 23.62, Bio-Rad Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.62, based on 446 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Rad Laboratories's current PE Ratio without NRI of 34.04 is 44.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Bio-Rad Laboratories and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Rad Laboratories's current PE Ratio without NRI is 34.04, which is 21% below median its own 10-year median of 43.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €278.74, compared to a current price of €260.40 — trading 6.6% below its estimated fair value. The current PE Ratio without NRI is 34.04, which is 21% below median its 10-year median of 43.17 and 44.1% above the Medical Devices & Instruments industry median of 23.62. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current PE Ratio without NRI is 34.04 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?
Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued.
The current stock price of €260.40 is trading 6.6% below its estimated GF Value™ of €278.74.
GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.
Key valuation signals for FRA:BUWA:
PE Ratio without NRI: 34.04 (21% below median its 10-year median of 43.17)
GF Value™: €278.74 vs. price of €260.40 (6.6% below fair value)
Industry Position: 44.1% above the Medical Devices & Instruments median (#289 of 446)
No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score
Get the complete analysis for FRA:BUWA
PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:BUWA has been successfully added to your 
